HC Wainwright & Co. reiterated coverage on NeuBase Therapeutics with a new price target

2/12/21 6:51:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

HC Wainwright & Co. reiterated coverage of NeuBase Therapeutics with a rating of Buy and set a new price target of $18.00 from $15.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NBSE

Date	Price Target	Rating	Analyst